The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Subscribe To Our Newsletter & Stay Updated
